Poseida Therapeutics Inc has a consensus price target of $20.5, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co. on March 8, 2024, December 11, 2023, and December 11, 2023. With an average price target of $16.67 between HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co., there's an implied 441.32% upside for Poseida Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/08/2024 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 549.58% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
12/11/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 224.79% | Piper Sandler | Edward Tenthoff | $8 → $10 | Maintains | Overweight | Get Alert |
12/11/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 549.58% | HC Wainwright & Co. | Arthur He | $15 → $20 | Maintains | Buy | Get Alert |
10/10/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 354.71% | Cantor Fitzgerald | Jennifer Kim | → $14 | Reiterates | Overweight → Overweight | Get Alert |
08/08/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 387.19% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | Buy → Buy | Get Alert |
05/23/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 387.19% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | Buy → Buy | Get Alert |
05/10/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 387.19% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | → Buy | Get Alert |
03/10/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 387.19% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | → Buy | Get Alert |
02/23/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 387.19% | HC Wainwright & Co. | Arthur He | → $15 | Maintains | Buy | Get Alert |
02/01/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 679.5% | Cantor Fitzgerald | Jennifer Kim | → $24 | Reiterates | → Overweight | Get Alert |
01/04/2023 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 387.19% | HC Wainwright & Co. | Swayampakula Ramakanth | → $15 | Initiates | → Buy | Get Alert |
08/09/2022 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 257.27% | Piper Sandler | Edward Tenthoff | $9 → $11 | Maintains | Overweight | Get Alert |
05/13/2022 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 192.31% | Piper Sandler | Edward Tenthoff | $19 → $9 | Maintains | Overweight | Get Alert |
01/07/2022 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 679.5% | Cantor Fitzgerald | Brian Cheng | → $24 | Initiates | → Overweight | Get Alert |
05/18/2021 | PSTX | Buy Now | Poseida Therapeutics | $3.08 | 1199.17% | BTIG | Justin Zelin | — | Initiates | → Buy | Get Alert |
The latest price target for Poseida Therapeutics (NASDAQ: PSTX) was reported by HC Wainwright & Co. on March 8, 2024. The analyst firm set a price target for $20.00 expecting PSTX to rise to within 12 months (a possible 549.58% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Poseida Therapeutics (NASDAQ: PSTX) was provided by HC Wainwright & Co., and Poseida Therapeutics reiterated their buy rating.
There is no last upgrade for Poseida Therapeutics.
There is no last downgrade for Poseida Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Poseida Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Poseida Therapeutics was filed on March 8, 2024 so you should expect the next rating to be made available sometime around March 8, 2025.
While ratings are subjective and will change, the latest Poseida Therapeutics (PSTX) rating was a reiterated with a price target of $0.00 to $20.00. The current price Poseida Therapeutics (PSTX) is trading at is $3.08, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.